CAC Scoring

Inclisiran: Where Will It Fit?

Inclisiran (Leqvio; Novartis) is now the first small interfering RNA (siRNA) therapy to be approved by the FDA to reduce low-density lipoprotein cholesterol (LDL-C). Inclisiran…

Enzymes in the Gut Microbiome As Contributors to Circulating Lipids

It is well established that dietary input combined with genetic predisposition can substantially alter blood lipid profiles and susceptibility of humans to diseases such as…

Lipoprotein(a) Medications Under Development

Lipoprotein(a) (Lp(a)) resembles an LDL-like lipoprotein with apolipoprotein(a) covalently bound with a disulfide link to apolipoprotein B on the particle surface. Lp(a)’s pro-inflammatory, pro-atherogenic, and…

Case Study: Aerobic Exercise and the Effects on Triglycerides for the Purpose of Cardiovascular Risk Reduction

Elevated triglycerides alter lipoprotein metabolism thus should be considered an independent risk factor for cardiovascular disease mortality. Altered lipoprotein metabolism can result in elevated plasma…

The Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Lipid Profile

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are novel, effective oral anti-hyperglycemic medications that inhibit glucose reabsorption in the proximal convoluted tubule of the kidney, independent of…

Practical Approaches to Dietary Management of Hypertriglyceridemia

Nutrition Recommendations for HypertriglyceridemiaHigh triglycerides (TG) are a target for atherosclerotic cardiovascular disease (ASCVD) risk reduction.1-5 Despite the use of statin therapy, ASCVD event rates…

Therapies for Treating Hypertriglyceridemia

Many observational studies have established a link between elevated triglycerides and adverse cardiovascular events.1 Experimental and Mendelian randomization studies have shown that triglyceride-rich lipoproteins participate…